Truist Securities Maintains Buy on Evolent Health, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating for Evolent Health, maintaining a price target of $33.
August 27, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating for Evolent Health, maintaining a price target of $33. This suggests confidence in the company's future performance.
The reaffirmation of a Buy rating and a specific price target by Truist Securities indicates a positive outlook on Evolent Health's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100